



February 18, 2015

Harvard Bioscience Appoints Ryan Atienza to Vice President of Sales at Its Denville Scientific Subsidiary

Mr. Atienza Joins Executive Leadership Team Responsible for North American Sales

HOLLISTON, Mass., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of equipment, instruments and solutions to advance life science, has appointed Ryan Atienza to Vice President of Sales, a newly created position, at its Denville Scientific subsidiary, effective February 16. Mr. Atienza will be a member of the executive leadership team responsible for North American sales.

Mr. Atienza brings more than a decade of experience working for healthcare and global life sciences companies, including selling life science consumables, instruments and equipment both direct and via distributors. Prior to joining Harvard Bioscience, he served as Manager, Business Development with American Express - Healthcare Solutions. Prior to this, he served as Director, Ophthalmic Business Consulting Group for Essilor of America, the leading manufacturer and wholesale distributor of optical lenses in the U.S. Earlier, from 2002 to 2012, he served in progressive sales leadership positions at Beaver-Visitec International, a company combining former ophthalmic business units from Becton, Dickinson & Company and Medtronic. Mr. Atienza holds an M.B.A. from Wake Forest University School of Business and B.A. in biology from Appalachian State University.

Jeffrey A. Duchemin, CEO and president of Harvard Bioscience, said, "Ryan Atienza brings a tremendous level of industry experience and leadership to Denville Scientific, and we are truly privileged to have him serve as the company's Vice President of Sales as well as on our executive leadership team. With our company's growth strategy, we thought it was important to appoint a dedicated sales leader to Denville. Having worked with Ryan before, I am confident that his insights will be instrumental to growing our North American product sales over the coming years."

Mr. Atienza said, "I am looking forward to working with Harvard Bioscience's management team on the sales and distribution of Denville Scientific's top-of-the-line products. With the opening of the new state-of-the-art distribution center in Charlotte, NC, I see a strong potential for growth and look forward to contributing to Denville's success."

Denville Scientific, which was acquired by Harvard Bioscience in 2009, is a distributor of molecular biology products, with a strong focus on liquid handling items utilized in research laboratories. Denville lab equipment includes extended length pipette tips, bench top tube chillers and self-cooling micro centrifuges.

About Harvard Bioscience

Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, GE Healthcare, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.

The Harvard Bioscience logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=23828>

Safe Harbor Statement

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, expectations regarding revenues and accretive earnings attributable to the acquisitions, statements or inferences about Harvard Bioscience's or management's beliefs or expectations, the company's anticipated future revenues and earnings, the strength of the company's market position and business model, the impact of acquisitions, the outlook for the life sciences industry, the company's business strategy, the positioning of the company for growth, the market demand and opportunity for the company's current products, or products it is developing or intends to develop, and the company's plans, objectives and intentions that are not historical facts. These statements involve risks and uncertainties, including among other things, unanticipated costs relating to the acquisitions; the company's failure to integrate the acquired businesses or technologies; the company's inability to manage its growth; competition from the company's competitors; technological changes resulting in the company's products becoming obsolete; the company's ability to retain key personnel; failure or inadequacy of the company's

information technology structure; and other factors that may cause the actual results to differ materially from the statements set forth in this press release. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Bioscience expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

CONTACT: Harvard Bioscience

Jeffrey A. Duchemin

President and Chief Executive Officer

Tel: (508) 893-8999

Investor and Public Relations:

Dian Griesel Int'l.

Cheryl Schneider/Susan Forman

(212) 825-3210